The effects of ivacaftor on CF fatty acid metabolism: An analysis from the GOAL study
Michael Glenn O'Connor, Adam Seegmiller, Michael Glenn O'Connor, Adam Seegmiller
Abstract
Background: Ivacaftor has produced significant improvement in certain individuals with cystic fibrosis (CF), though the full metabolic effects of treatment remain unknown. Abnormalities in fatty acid metabolism have previously been shown to be a characteristic of CFTR dysfunction. We hypothesized that as a reflection of this clinical improvement, ivacaftor would improve plasma fatty acid levels and decrease urine prostaglandin E metabolite levels.
Methods: This study analyzed plasma fatty acid levels and urine prostaglandin E metabolites (PGE-M) in 40 subjects with CF participating in the G551D observational (GOAL) study who demonstrated response to the medication by a significant decrease in sweat Cl levels. Paired samples were analyzed before and after 6months of ivacaftor treatment.
Results: Linoleic acid and docosahexaenoic acid levels, which are typically low in individuals with CF, did not significantly increase with ivacaftor treatment. However, arachidonic acid levels did decrease with ivacaftor treatment and there was a significant decrease in the arachidonic acid metabolite PGE-M as measured in the urine [median: before treatment 17.03ng/mg Cr; after treatment 9.06ng/mg Cr; p<0.001]. Furthermore, there were fatty acid age differences observed, including pediatric participants having significantly greater linoleic acid levels at baseline.
Conclusion: Ivacaftor reduces inflammatory PGE without fully correcting the plasma fatty acid abnormalities of CF. Age-related differences in fatty acid levels were observed, that may be a result of other clinical factors, such as diet, clinical care, or drug response.
Keywords: Cystic fibrosis; Fatty acids; Ivacaftor; Prostaglandin E.
Copyright © 2016 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
Figures
![Figure 1. Urine Prostaglandin E Metabolite (PGE-M)…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5241173/bin/nihms805032f1.jpg)
Figure 2. Urine Prostaglandin E Metabolite (PGE-M)…
Figure 2. Urine Prostaglandin E Metabolite (PGE-M) Levels by Age
(A) Baseline urine PGE-M by…
- In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.McGarry ME, Illek B, Ly NP, Zlock L, Olshansky S, Moreno C, Finkbeiner WE, Nielson DW. McGarry ME, et al. Pediatr Pulmonol. 2017 Apr;52(4):472-479. doi: 10.1002/ppul.23659. Epub 2017 Jan 9. Pediatr Pulmonol. 2017. PMID: 28068001 Free PMC article. Clinical Trial.
- GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1).Davies JC, Van de Steen O, van Koningsbruggen-Rietschel S, Drevinek P, Derichs N, McKone EF, Kanters D, Allamassey L, Namour F, de Kock H, Conrath K. Davies JC, et al. J Cyst Fibros. 2019 Sep;18(5):693-699. doi: 10.1016/j.jcf.2019.05.006. Epub 2019 May 27. J Cyst Fibros. 2019. PMID: 31147302 Clinical Trial.
- Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.Ratjen F, Hug C, Marigowda G, Tian S, Huang X, Stanojevic S, Milla CE, Robinson PD, Waltz D, Davies JC; VX14-809-109 investigator group. Ratjen F, et al. Lancet Respir Med. 2017 Jul;5(7):557-567. doi: 10.1016/S2213-2600(17)30215-1. Epub 2017 Jun 9. Lancet Respir Med. 2017. PMID: 28606620 Clinical Trial.
- Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis.O'Reilly R, Elphick HE. O'Reilly R, et al. Drug Des Devel Ther. 2013 Aug 30;7:929-37. doi: 10.2147/DDDT.S30345. eCollection 2013. Drug Des Devel Ther. 2013. PMID: 24039402 Free PMC article. Review.
- Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.Zhang W, Zhang X, Zhang YH, Strokes DC, Naren AP. Zhang W, et al. Drugs Today (Barc). 2016 Apr;52(4):229-37. doi: 10.1358/dot.2016.52.4.2467205. Drugs Today (Barc). 2016. PMID: 27252987 Free PMC article. Review.
- Observational Study
- Research Support, N.I.H., Extramural
- Adult
- Aminophenols / administration & dosage*
- Arachidonic Acid* / blood
- Arachidonic Acid* / metabolism
- Child
- Chloride Channel Agonists / administration & dosage
- Cystic Fibrosis Transmembrane Conductance Regulator / genetics
- Cystic Fibrosis* / drug therapy
- Cystic Fibrosis* / genetics
- Cystic Fibrosis* / immunology
- Cystic Fibrosis* / metabolism
- Drug Monitoring / methods
- Fatty Acids, Monounsaturated* / blood
- Fatty Acids, Monounsaturated* / metabolism
- Female
- Humans
- Inflammation Mediators / metabolism
- Linoleic Acid* / blood
- Linoleic Acid* / metabolism
- Lipid Metabolism / drug effects*
- Male
- Mutation
- Pilot Projects
- Prostaglandins E / metabolism*
- Prostaglandins E / urine
- Quinolones / administration & dosage*
- Aminophenols
- Chloride Channel Agonists
- Fatty Acids, Monounsaturated
- Inflammation Mediators
- Prostaglandins E
- Quinolones
- Cystic Fibrosis Transmembrane Conductance Regulator
- ivacaftor
- palmitoleic acid
- Arachidonic Acid
- Linoleic Acid
- Full Text Sources
- Other Literature Sources
- Medical
![Figure 2. Urine Prostaglandin E Metabolite (PGE-M)…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5241173/bin/nihms805032f2.jpg)
Source: PubMed